Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2015

View Archived Issues

Shionogi presents highlights of first quarter of fiscal 2015

Novel potent cross-reactive MAb that neutralizes influenza A virus

Novo Nordisk reviews second quarter 2015

New findings concerning the pathophysiology of spinal cord injury

Emergent BioSolutions plans to spin off immuno-oncology business

German and U.S. team presents omega-3 PUFA analogues

Allergan divulges prostanoid receptor antagonists

Piramal introduces EZH2 inhibitors

Daiichi Sankyo discloses LCAT activators

MabVax and Rockefeller University enter into research collaboration agreement

Inovio and MedImmune establish cancer vaccine collaboration

Anti-IL-23 therapy shows promise for the treatment of psoriasis

Sanofi, Evotec and Apeiron Biologics collaborate on development of immuno-oncology treatments

Phase I study investigates DNA vaccine pTVG-AR for metastatic prostate cancer

Merck & Co. divulges MGAT2 inhibitors

Cancer Research UK awards grant to Newcastle University's Northern Institute of Cancer Research

Sanofi files application for alirocumab approval in Japan

Torii and ALK's Japanese cedar pollen SLIT improves rhinitis symptoms in phase II/III trial

FDA grants orphan drug designation to recombinant IVIG-mimetic GL-2045

RegeneRx updates on clinical development of RGN-259

Antibe Therapeutics completes phase I development of ATB-346

SAGE Therapeutics and FDA agree design of phase III SAGE-547 trial under SPA

MJFF to fund preclinical study of ANAVEX 2-73 for Parkinson's disease

ProMetic Life Sciences completes first plasminogen dosing round in phase I trial

Turing acquires Daraprim U.S. rights from Impax

FDA approves Keveyis for primary hyperkalemic and hypokalemic periodic paralysis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...